Related Experiment Video

Updated: Aug 10, 2026

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

Immunization of high-risk infants younger than 18 months of age with split-product influenza vaccine

J R Groothuis1, M J Levin, G P Rabalais

  • 1Department of Pediatrics, University of Colorado School of Medicine, Denver.

Pediatrics
|June 1, 1991
PubMed

Insights

This study evaluated influenza vaccine safety and effectiveness in high-risk infants. While generally safe, responses varied by age and influenza strain, indicating a need for optimized vaccination strategies for vulnerable children.

Area of Science:

  • Pediatric Infectious Diseases
  • Vaccinology
  • Immunology

Background:

  • Influenza poses a significant risk of severe illness in young children with underlying cardiopulmonary conditions.
  • Very young children, particularly those with bronchopulmonary dysplasia and congenital heart disease, are a high-risk population for influenza complications.

Purpose of the Study:

  • To assess the immunogenicity and safety of an influenza split-product vaccine.
  • To evaluate vaccine responses in infants aged 3 to 18 months with specific cardiopulmonary diseases.

Main Methods:

  • A 4-year study involving 113 children (3-18 months) with bronchopulmonary dysplasia and congenital heart disease.
  • Sera were collected pre- and post-immunization for hemagglutination inhibition testing.
  • Adverse reactions were monitored in 95 children.

Main Results:

  • Seroresponses were specific to age and influenza antigen, with A/Mississippi (H3N2) showing the highest response (97%).
  • Children over 6 months demonstrated better seroresponses to A/Leningrad (H3N2) and B/Victoria compared to younger infants.
  • Adverse reactions were infrequent (9%) and predominantly mild.

Conclusions:

  • Influenza vaccination is generally safe in this high-risk pediatric population.
  • Age and antigen specificity of immune responses highlight the need for tailored immunization strategies.
  • Further research is required to understand immunologic mechanisms and optimize influenza prevention in very young, high-risk children.

More Related Videos

An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers06:34

An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers

Published on: December 1, 2017

Assessing Respiratory Immune Responses to Haemophilus Influenzae06:32

Assessing Respiratory Immune Responses to Haemophilus Influenzae

Published on: June 29, 2021

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Smallpox01:24

Smallpox

Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.
Influenza01:27

Influenza

Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...